Using an ensemble feature selection approach, this study successfully identified key biomarkers, including ABAT, C8B, FBXL3, and ZFP1, providing valuable insights into NAFLD to HCC disease progression. Here, FBXL3 is linked to metabolic dysfunction-associated steatotic liver disease.